Novavax Shifts From COVID Sales to R&D Focus While Updating 2025 Forecast

MSN
2025.11.25 13:49
portai
I'm PortAI, I can summarize articles.

Novavax, Inc. (NASDAQ:NVAX) announced its third-quarter 2025 financial results, highlighting a strategic shift from COVID-19 sales to a focus on research and development, particularly in collaboration with Sanofi. The company is recognized as one of the most oversold biotech stocks to invest in.

Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer